Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy

Pharmacotherapy
Leticia R VillelaSachin R Shah

Abstract

Pemetrexed is a newly approved antifolate agent for the treatment of malignant pleural mesothelioma (MPM) and metastatic non-small cell lung cancer (NSCLC). We performed a PubMed/MEDLINE database search to identify relevant literature from January 1966-April 2005. Bibliographies from identified references were searched as well, as were abstracts from the 2004 and 2005 proceedings of the American Society of Clinical Oncology. We discuss the pharmacology of pemetrexed, describing its mechanism of action and comparing it with methotrexate. The pharmacokinetics and pharmacodynamics of pemetrexed are described to provide a better understanding of the properties of this drug. Therapeutic uses are assessed, beginning with the approved indications of MPM and NSCLC. However, pemetrexed has been studied in numerous phase II trials for other types of solid malignancies, and completed trials are reviewed. Data on adverse effects and drug interactions are also provided. Finally, dosing and administration are reviewed, including appropriate premedication. Premedication, including administration of steroids and vitamin supplements, has been shown to decrease the frequency and severity of pemetrexed toxicities. Pemetrexed should be used as a s...Continue Reading

References

Mar 1, 1991·International Journal of Radiation Oncology, Biology, Physics·P Maasilta
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Jan 20, 1993·Journal of the National Cancer Institute·I W Dimery, W K Hong
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S T Ong, N J Vogelzang
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·U GatzemeierM Voi
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethC M Lindley
Jun 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ManegoldW ten Bokkel-Huinink
Feb 25, 1998·The Journal of Thoracic and Cardiovascular Surgery·H I PassI R Feuerstein
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F CardenalR Rosell
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J ByrneB W Robinson
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J J RusthovenJ Iglesias
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jun 10, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ManegoldK Krejcy
Jan 11, 2002·The New England Journal of Medicine·Kazumasa NodaUNKNOWN Japan Clinical Oncology Group
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Mar 5, 2002·British Journal of Cancer·J M W van HaarstJ P van Meerbeeck
May 23, 2002·Seminars in Oncology·Hilary Calvert
Jun 22, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J ClarkeS P Ackland
Dec 24, 2002·Cancer Biology & Therapy·Donald S Coffey
Feb 7, 2003·Seminars in Oncology·I David Goldman, Rongbao Zhao
Feb 7, 2003·Seminars in Oncology·Clet NiyikizaPaul A Bunn
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio V ScagliottiJames J Rusthoven
May 2, 2003·Expert Review of Anticancer Therapy·Alex A Adjei
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J VogelzangPaolo Paoletti
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MartinC Zielinski
Sep 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BajettaW John
Oct 28, 2003·Investigational New Drugs·R ThödtmannA- R Hanauske
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael Castro
Jan 23, 2004·The New England Journal of Medicine·Alexander Spira, David S Ettinger
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jun 1, 2004·The Oncologist·Rongbao Zhao, I David Goldman
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian MonneratDavid S Ettinger
Oct 13, 2004·The Oncologist·Maitreyee HazarikaRichard Pazdur
Nov 24, 2004·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lawrence A TrisselDelshalonda S Ingram
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottMichael B Atkins
Jan 22, 2005·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 9, 2005·Seminars in Oncology·Mark A Socinski
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giorgio V Scagliotti
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Oct 14, 2005·The New England Journal of Medicine·Bruce W S Robinson, Richard A Lake

❮ Previous
Next ❯

Citations

Feb 3, 2007·Nature Reviews. Drug Discovery·Ching-Hon Pui, Sima Jeha
Aug 2, 2007·Expert Opinion on Therapeutic Targets·Khaled Fernainy, Nabil Saba
Jul 1, 2009·Expert Opinion on Drug Discovery·Pedro Mestres, Andrea Morguet
Sep 6, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Belen EguiaJacques Cadranel
Aug 19, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ilya G GlezermanSurya V Seshan
Mar 10, 2009·Cancer Treatment Reviews·Emilio EstebanAlejo Cassinello
Dec 23, 2008·Seminars in Hematology·Sima Jeha
Mar 24, 2016·Expert Opinion on Drug Safety·Tania Losanno, Cesare Gridelli
Aug 26, 2014·Biochemical and Biophysical Research Communications·Xinhui ZhuZhiming Cui
Feb 3, 2015·Bulletin du cancer·Hassan Izzedine
Nov 1, 2016·Expert Opinion on Pharmacotherapy·Xavier Thomas, Caroline Le Jeune
Jun 3, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A-R HanauskeG Giaccone
Jan 29, 2013·Journal of Neuro-oncology·Priya KumthekarJeffrey J Raizer
Jul 29, 2017·Journal of Medical Case Reports·Yassir SbittiMohamed Ichou
Jun 22, 2020·European Journal of Clinical Pharmacology·Louis MagaliMousson Christiane
Oct 9, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Mustafa KorkmazMehmet Artaç
Aug 9, 2020·Annales de dermatologie et de vénéréologie·M SarrazinD Staumont-Sallé
May 7, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M RansonC Twelves

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.